Whitepaper Spotlight: Proactive Biomarker Planning to Optimize Clinical Trials
Oncology drugs developed through a biomarker-guided precision medicine design are 38% more likely to be commercialized. But success relies on following a plan from the start -- learn how in this free whitepaper
BioNTech
David Dorward; Ph.D.; National Institute of Allergy and Infectious Diseases (NIAID)
SLAS